Recent advances in small molecule inhibitors of interleukin‑1 receptor-associated kinase
10.16438/j.0513-4870.2022-0695
- VernacularTitle:白细胞介素-1受体相关激酶4小分子抑制剂的研究进展
- Author:
Jing-cheng YU
1
;
Zheng-chuan DONG
2
;
Rui-xu MU
3
;
Le-yuan CHEN
3
;
Yi-liang LI
3
;
Wen-bin HOU
3
Author Information
1. Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
2. Tianjin Chase Sun Pharmaceutical Co., Ltd., Tianjin 301700, China
3. Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China
- Publication Type:Research Article
- Keywords:
interleukin‑1 receptor-associated kinase 4;
TLRs/IL-1R signaling pathway;
inflammatory disease;
antitumor;
small molecule inhibitor
- From:
Acta Pharmaceutica Sinica
2023;57(1):27-38
- CountryChina
- Language:Chinese
-
Abstract:
Interleukin-1 receptor associated kinase 4 (IRAK-4), acting as a serine threonine kinase, is considered as a key signal node for the transduction of IL-1R family and TLRs signal pathway. Studies have found that IRAK-4 has a hand in many signal pathways, involving the inflammatory response of human joints, intestines, liver and nervous system, as well as other autoimmune diseases. It is also one of the causes of drug resistance of some cancer cells. Therefore, IRAK-4 tends to be an effective therapeutic target for inflammatory diseases and cancer. The prospects for the development of drugs in this pathway is to develop novel IRAK-4 small molecule inhibitors and investigate their safety and effectiveness, enrich the clinical treatment of inflammatory and cancer diseases finally. This paper classified and summarized the latest research progress on small molecule inhibitors of IRAK-4 signaling pathway according to structures of the compounds, in order to provide assistances and references for the research and development of related drugs.
